Literature DB >> 21618471

Transforming growth factor-β1 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells.

Richard Beatson1, Daisy Sproviero, John Maher, Scott Wilkie, Joyce Taylor-Papadimitriou, Joy M Burchell.   

Abstract

Chinese hamster ovary (CHO) cells are widely used for the production of recombinant proteins for clinical use as well as academic research. They are particularly important for the production of glycoproteins where bacteria cannot be used. TGFβ1 is a potent cytokine highly conserved across species with multiple immunological and non-immunological effects. We have discovered that CHOK1, the CHO clone most commonly used by the pharmaceutical industry, constitutively secretes latent TGFβ1 and that this hamster TGFβ1 is active on human cells inducing profound immunological effects. As far as we are aware, the production of TGFβ1 by CHOK1 cells has not been reported before in the literature. As TGFβ1 exerts powerful and pleiotropic effects on diverse cell types, and as CHO cells are used to produce a large number of clinical and non-clinical products, our findings are highly relevant to studies that rely on recombinant proteins.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21618471     DOI: 10.1002/bit.23217

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  8 in total

1.  Host cell protein dynamics in recombinant CHO cells: impacts from harvest to purification and beyond.

Authors:  Catherine Em Hogwood; Daniel G Bracewell; C Mark Smales
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

2.  Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry.

Authors:  Qingchun Zhang; Andrew M Goetze; Huanchun Cui; Jenna Wylie; Steve Trimble; Art Hewig; Gregory C Flynn
Journal:  MAbs       Date:  2014-02-11       Impact factor: 5.857

Review 3.  The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control.

Authors:  Daniel G Bracewell; Richard Francis; C Mark Smales
Journal:  Biotechnol Bioeng       Date:  2015-07-14       Impact factor: 4.530

4.  TGF-β contamination of purified recombinant GDF15.

Authors:  Oddrun Elise Olsen; Anette Skjærvik; Berit Fladvad Størdal; Anders Sundan; Toril Holien
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

5.  Identification of chlorophyll a-b binding protein AB96 as a novel TGFβ1 neutralizing agent.

Authors:  Steven Lynham; Fabio Grundland Freile; Natasha M Puri; Nicola O'Reilly; Graham H Mitchell; Timothy N C Wells; Merlin Willcox; Richard Beatson
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

6.  Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth.

Authors:  Alessandra Rosati; Liberato Marzullo; Margot De Marco; Vanessa Gauttier; Sabrina Pengam; Caroline Mary; Bianca Ranieri; Anna Basile; Michela Festa; Antonia Falco; Francesca Reppucci; Anna Lisa Cammarota; Fausto Acernese; Vincenzo De Laurenzi; Gianluca Sala; Sergio Brongo; Masayuki Miyasaka; Shabnam Shalapour; Bernard Vanhove; Nicolas Poirier; Roberta Iaccarino; Michael Karin; Maria Caterina Turco
Journal:  Cell Death Discov       Date:  2022-03-03

7.  Quantitative definition and monitoring of the host cell protein proteome using iTRAQ - a study of an industrial mAb producing CHO-S cell line.

Authors:  Lesley M Chiverton; Caroline Evans; Jagroop Pandhal; Andrew R Landels; Byron J Rees; Peter R Levison; Phillip C Wright; C Mark Smales
Journal:  Biotechnol J       Date:  2016-06-22       Impact factor: 4.677

8.  Host cell protein detection gap risk mitigation: quantitative IAC-MS for ELISA antibody reagent coverage determination.

Authors:  Daniel M Waldera-Lupa; Yvonne Jasper; Pia Köhne; Ronja Schwichtenhövel; Heiner Falkenberg; Thomas Flad; Peter Happersberger; Bernd Reisinger; Alireza Dehghani; Roland Moussa; Thomas Waerner
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.